Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians

Mary Madison, RN, RAC-CT, CDP
Clinical Consultant – Briggs Healthcare

IDSA (Infectious Diseases Society of America) has published an updated (May 6, 2022) resource: Management of Drug Interactions with Nirmatrelvir/Ritonavir (Paxlovid): Resource for Clinicians.

Here’s a couple of examples of what you’ll find within this extensive resource:


Paxlovid is being used to treat mild-to-moderate COVID-19 in high-risk patients. As always, knowledge of the individual’s entire medication regimen (prescription and OTC) is critical when adding any new medication but especially important with Paxlovid. I encourage you to download, share and use this valuable resource to keep your patients safe.